Cyclacel Pharmaceuticals Inc (CYCC)

4.41 -0.55  -11.09% NASDAQ Aug 2, 09:22 USD
View Full Chart
Price Chart
View All CYCC News

News

View All Events

Events

Date Type Description
08/16/2021 Earnings Results Q2 2021 Earnings Results
08/16/2021 16:30 EST Earnings Calls Q2 2021 Earnings Call
05/12/2021 Earnings Results Q1 2021 Earnings Results
05/12/2021 16:30 EST Earnings Calls Q1 2021 Earnings Call
02/25/2021 Earnings Results Q4 2020 Earnings Results
02/25/2021 16:30 EST Earnings Calls Q4 2020 Earnings Call
11/11/2020 Earnings Results Q3 2020 Earnings Results
11/11/2020 16:30 EST Earnings Calls Q3 2020 Earnings Call
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.
  • URL: https://www.cyclacel.com
  • Investor Relations URL: http://investor.cyclacel.com/
  • HQ State/Province: New Jersey
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Value
  • Next Earnings Release: Aug. 16, 2021
  • Last Earnings Release: May. 12, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.